Oxford Vaccine Group

Last updated

Oxford Vaccine Group
Formation1994
PurposeResearch and clinical trials
Location
Director
 Professor Andrew J Pollard
Parent organization
 University of Oxford
AffiliationsUKCRC registered
Staff
75
Website www.ovg.ox.ac.uk

The Oxford Vaccine Group (OVG) is a vaccine research group within the Department of Paediatrics at the University of Oxford. It was founded in 1994 by Professor E. Richard Moxon, was initially based at the John Radcliffe Hospital, and moved in 2003 to its current location in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford, England. [1] The group, led by Professor Andrew Pollard since 2001, comprises around 75 members across a number of disciplines, including consultants in paediatrics and vaccinology, clinical research fellows, research nurses, statisticians, post-doctoral laboratory scientists, research assistants and DPhil students.

Contents

OVG came to public prominence in 2020 for the vaccine it created to combat COVID-19.

Aims and background

OVG carries out research on vaccines to improve human health. It works to enhance the understanding of immunity, studies the epidemiology of infectious diseases, and conducts clinical trials into new and improved vaccines for children and adults. Research by Richard Moxon into the public health impact of Haemophilus influenzae type b (Hib) invasive disease in the UK, and efficacy studies of the Hib conjugate vaccine in UK children, led to the founding of OVG in 1994. [2] Since then OVG has particularly specialised in research into meningococcal disease and vaccines to prevent the disease. OVG has been involved with the development of the new vaccine against MenB which was licensed in Europe in 2013. [3] [4] The Group has also carried out research on pneumococcal vaccines, typhoid vaccines and, more recently, new vaccines against Ebola.

OVG is a research group within the Department of Paediatrics at the University of Oxford. It is a UK Clinical Research Collaboration (UKCRC) registered clinical trials unit working in collaboration with the Primary Care Unit Clinical Trials Unit (Nuffield Department of Primary Care Health Sciences) and the Jenner Institute at the University of Oxford. [5] [6] It is also a participant in the UK Paediatric Vaccine Group (UKPVG) [7] and contributes to the Oxford University Hospitals NHS Trust’s tertiary Paediatric Infectious Disease and Immunology Service. [8] All OVG trials are listed on the UK Clinical Trials Gateway. OVG supports the All Trials Campaign. [9]

Professor Andrew Pollard, OVG’s Director, was appointed Chair of the Joint Committee on Vaccination and Immunisation (JCVI) in March 2014. [10] Senior staff at OVG are periodically asked to give expert opinions on aspects of vaccines and infectious disease, especially meningococcal disease. For example the 2015 announcement that 14- to 18-year-olds in the UK are to be vaccinated against MenW disease, [11] and the 2012 European Medicines Agency (EMA) recommendation for approval of a new meningitis B vaccine. [12]

Research activity

Since 2001, OVG has enrolled over 12,500 adults and children into clinical trials in the Thames Valley area of England. OVG research has included:

Funding

The OVG is funded not only by its alma mater and UK government bodies such as the Medical Research Council (MRC), National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI), and Public Health England (PHE), [30] but also private UK charities like the Wellcome Trust, Meningitis Research Foundation, Meningitis UK and Action Medical Research. [31]

The group has earned attention from international funders like the Bill & Melinda Gates Foundation (BMGF), the Global Alliance for Vaccines and Immunization (GAVI), and the World Health Organization (WHO) as well as undisclosed vaccine manufacturers. [31]

The probable commercial success of the ChAdOx1-based AZD1222 product led the BMGF to prod the OVG into a deal with AstraZeneca under which the financial reward would be split between partners, instead of "donat(ing) the rights to its promising coronavirus vaccine to any drugmaker" in a misguided effort "to provide medicines preventing or treating COVID-19 at a low cost or free of charge." Under the extant deal, the OVG (or the trustees of Oxford University) will have another revenue stream with which to finance its activities. [32]

Vaccine Knowledge Project

In 2011, the group launched the Vaccine Knowledge Project, funded by the Oxford Biomedical Research Centre. [33] The project website aims to provide independent, evidence-based information about vaccines and infectious diseases. The NHS Choices website lists the Vaccine Knowledge website as a recommended external link on several of its pages. [34] [35] [36] The website has also been referenced in the national media in the UK, particularly during the 2014-15 US measles outbreak originating in Disneyland California. [37] [38] The project is a member of the Vaccine Safety Net. [39]

Awards

In November 2021 the team were awarded a Pride of Britain Award for their work on the COVID-19 vaccine. [40]

Related Research Articles

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

<i>Neisseria meningitidis</i> Species of bacterium that can cause meningitis

Neisseria meningitidis, often referred to as meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis. The bacterium is referred to as a coccus because it is round, and more specifically a diplococcus because of its tendency to form pairs.

<span class="mw-page-title-main">Meningococcal disease</span> Medical condition

Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis. It has a high mortality rate if untreated but is vaccine-preventable. While best known as a cause of meningitis, it can also result in sepsis, which is an even more damaging and dangerous condition. Meningitis and meningococcemia are major causes of illness, death, and disability in both developed and under-developed countries.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland may choose to accept its advice.

<span class="mw-page-title-main">Hib vaccine</span> Haemophilus influenzae type B vaccine

The Haemophilus influenzae type B vaccine, also known as Hib vaccine, is a vaccine used to prevent Haemophilus influenzae type b (Hib) infection. In countries that include it as a routine vaccine, rates of severe Hib infections have decreased more than 90%. It has therefore resulted in a decrease in the rate of meningitis, pneumonia, and epiglottitis.

John Bennett Robbins was a senior investigator at the National Institutes of Health (NIH), best known for his contribution to the development of the vaccine against bacterial meningitis with his colleague Rachel Schneerson. He conducted research on the Bethesda, Maryland campus of the NIH from 1970 until his retirement at the age of 80 in 2012. During his tenure, he worked in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Food and Drug Administration’s biologics laboratories on location.

<span class="mw-page-title-main">JN-International Medical Corporation</span> Pharmaceutical company in Nebraska, United States

JN-International Medical Corporation (JNIMC) is a U.S.-based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska.

NmVac4-A/C/Y/W-135 is the commercial name of the polysaccharide vaccine against the bacterium that causes meningococcal meningitis. The product, by JN-International Medical Corporation, is designed and formulated to be used in developing countries for protecting populations during meningitis disease epidemics.

<span class="mw-page-title-main">Meningitis</span> Inflammation of the membranes around the brain and spinal cord

Meningitis is acute or chronic inflammation of the protective membranes covering the brain and spinal cord, collectively called the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, nausea, vomiting, and an inability to tolerate light or loud noises. Young children often exhibit only nonspecific symptoms, such as irritability, drowsiness, or poor feeding. A non-blanching rash may also be present.

<span class="mw-page-title-main">Meningococcal vaccine</span> Vaccines used to prevent infection by Neisseria meningitidis

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">African meningitis belt</span>

The African meningitis belt is a region in sub-Saharan Africa where the rate of incidence of meningitis is very high. It extends from Senegal to Ethiopia, and the primary cause of meningitis in the belt is Neisseria meningitidis.

MenAfriVac is a vaccine developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age against meningococcal bacterium Neisseria meningitidis group A. The vaccine costs less than US$0.50 per dose.

The Vaccine Damage Payment is a provision of the welfare state in the United Kingdom that provides a substantial payment for people who can show that they have suffered a vaccine injury.

Noni E. MacDonald is a Canadian physician. She is a Professor in the Department of Pediatrics and former Dean of the Faculty of Medicine at Dalhousie University. In 2019, MacDonald was awarded the Order of Nova Scotia and Order of Canada.

Sir Andrew John Pollard is a Professor of Paediatric Infection and Immunity at the University of Oxford and a Fellow of St Cross College, Oxford. He is an Honorary Consultant Paediatrician at John Radcliffe Hospital and the Director of the Oxford Vaccine Group. He is the Chief Investigator on the University of Oxford COVID-19 Vaccine trials and has led research on vaccines for many life-threatening infectious diseases including typhoid fever, Neisseria meningitidis, Haemophilus influenzae type b, streptococcus pneumoniae, pertussis, influenza, rabies, and Ebola.

Helen Aspasia Petousis-Harris is a New Zealand vaccinologist and associate professor in the Department of General Practice and Primary Health Care at the University of Auckland. She has been involved in research related to vaccination in New Zealand since 1998, with her main areas of focus being vaccine safety and effectiveness. Petousis-Harris has had a variety of lead roles in New Zealand and international organisations that focus on vaccination and is a regular media spokesperson in this field, especially during the COVID-19 pandemic.

Maheshi N. Ramasamy is a British-Sri Lankan physician and lecturer. She is currently working as one of the chief investigators at the Oxford Vaccine Group.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand.

<span class="mw-page-title-main">The Green Book (immunisation guidance, UK)</span> Book about vaccination

Immunisation against infectious disease, popularly known as The Green Book, provides information on vaccines for vaccine-preventable diseases. It acts as a guide to the UK's vaccination schedule for health professionals and health departments that give vaccines in the United Kingdom.

Helen Siobhan Marshall is an Australian medical researcher who is Professor of Vaccinology at the University of Adelaide. She was named the South Australian of the Year for 2022.

References

  1. ↑ Oxford Vaccine Group website. Retrieved 25 June 2015
  2. ↑ Biography of Richard Moxon, The Jenner Institute website, University of Oxford. Retrieved 25 June 2015
  3. 1 2 Sarah Boseley, Health Editor (15 May 2008). "Meningitis B tests raise hope of vaccine". The Guardian. Retrieved 25 June 2015.{{cite news}}: |author= has generic name (help)
  4. ↑ Denis Campbell (16 November 2012). "Doctors hail meningitis vaccine 'breakthrough'". The Guardian. Retrieved 25 June 2015.
  5. ↑ "Primary Care and Vaccines Collaborative Clinical Trials Unit website. Retrieved 25 June 2015". Archived from the original on 27 November 2015. Retrieved 4 August 2015.
  6. ↑ List of registered clinical trials units on the UK Clinical Research Collaboration website. Retrieved 25 June 2015
  7. ↑ List of UKPVG participating organisations on the UK Paediatric Vaccine Group website. Retrieved 25 June 2015
  8. ↑ Paediatric Infectious Disease and Immunology website. Retrieved 25 June 2015
  9. ↑ Oxford Vaccine Group signature on the All Trials Campaign website. Retrieved 25 June 2015
  10. ↑ Joint Committee on Vaccination and Immunisation membership. Retrieved 25 June 2015
  11. ↑ Science Media Centre, 15 March 2015. Retrieved 25 June 2015
  12. ↑ Science Media Centre, 16 November 2012. Retrieved 25 June 2015
  13. ↑ "Meningitis C vaccine 'wears off in early teens'". BBC News. 7 May 2010. Retrieved 25 June 2015.
  14. ↑ Perrett KP, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clinical Infectious Diseases 2010 Jun 15;50(12):1601-10
  15. ↑ "Teen jab theory over meningitis C". BBC News. 6 June 2008. Retrieved 25 June 2015.
  16. ↑ "Meningitis C vaccine 'wears off in early teens'". BBC News. 7 May 2010. Retrieved 25 June 2015.
  17. ↑ Fergus Walsh (24 May 2006). "I am testing new bird flu jab". BBC News. Retrieved 25 June 2015.
  18. ↑ Leroux-Roels I, et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine 2009 Nov 16;27(49):6918-25.
  19. ↑ Fergus Walsh (20 October 2006). "Meningitis B vaccine trials begin". BBC News. Retrieved 25 June 2015.
  20. ↑ "Child swine flu vaccine trial results published". BBC News. 28 May 2010. Retrieved 25 June 2015.
  21. ↑ "Children respond well to swine flu vaccines, trial shows". The Guardian. 28 May 2010. Retrieved 25 June 2015.
  22. ↑ Waddington CS, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010;340:c2649
  23. ↑ Reg Little (18 February 2010). "Never-ending war on disease". The Oxford Times. Retrieved 25 June 2015.
  24. ↑ EUCLIDS work packages. Retrieved 25 June 2015
  25. ↑ Fergus Walsh (6 January 2015). "Ebola: New vaccine trial begins". BBC News. Retrieved 25 June 2015.
  26. ↑ "Oxford University doctors and scientists start trials for new Ebola vaccine". ITV News. 6 January 2015. Retrieved 25 June 2015.
  27. ↑ Transcript of Oral Answers to Questions – Prime Minister – in the House of Commons at 11:30 am on 14 January 2015. Retrieved 25 June 2015
  28. ↑ Gallagher, James (20 July 2020). "Coronavirus: Oxford vaccine triggers immune response". BBC . Retrieved 21 July 2020.
  29. ↑ "Oxford University breakthrough on global COVID-19 vaccine". Oxford University. 23 November 2020.
  30. ↑ "Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children". University of Oxford, Department of Paediatrics, Level 2, Children's Hospital, John Radcliffe, Headington, Oxford, OX3 9DU. 17 April 2020.
  31. 1 2 "Oxford Vaccine Group". University of Oxford Medical Sciences Division. April 2014.
  32. ↑ Hancock, Jay (25 August 2020). "They Pledged to Donate Rights to Their COVID Vaccine, Then Sold Them to Pharma". KAISER FAMILY FOUNDATION. Kaiser Health News.
  33. ↑ Vaccine Knowledge homepage. Retrieved 25 June 2015
  34. ↑ NHS Choices page on the MenC vaccine with external link to Vaccine Knowledge website. Retrieved 25 June 2015
  35. ↑ NHS Choices page on the 3-in-1 teenage booster vaccine with external link to Vaccine Knowledge website. Retrieved 25 June 2015
  36. ↑ NHS Choices page on Vaccine Myths with external link to Vaccine Knowledge website. Retrieved 25 June 2015
  37. ↑ Claire Armitstead (2 February 2015). "Roald Dahl becomes sage of US measles outbreak". The Guardian. Retrieved 25 June 2015.
  38. ↑ Jules Montague (10 February 2015). "We should listen to Roald Dahl, not Jenny McCarthy, on vaccinating our children". The Guardian. Retrieved 25 June 2015.
  39. ↑ "Vaccine Safety Net: members". Vaccine Safety Net. Retrieved 3 January 2021.
  40. ↑ "Pride of Britain Awards" . Retrieved 4 November 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.